4587.T
PeptiDream Inc.
プライム · 医薬品 · 医薬品 · JP
JPY 1,098.00
+2.09%Aug 12, 2026, 06:43 UTC
PeptiDream announced on August 12 that it received a milestone payment from Novartis for the initiation of a Phase 1 clinical trial of a compound created through their joint research.
Source:Aug 12, 2026, 06:30 UTC
PeptiDream announced its IFRS results for the first half of 2026 (January-June), with a consolidated net loss of 1.99 billion yen, narrowing from a loss of 2.12 billion yen in the same period last year.
Source:Aug 12, 2026, 02:00 UTC
PeptiDream announced plans to launch its first proprietary drug by 2032, with a Phase 1 clinical trial for a kidney cancer radiopharmaceutical candidate started in July 2026.
Source:Jul 13, 2026, 07:57 UTC
PeptiDream announced the first dosing in a US clinical trial for its renal cancer radiopharmaceutical candidate PD-32766.
Source: